Lys1479
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.2
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys1479  -  SCN5A (human)

Site Information
NFNQQKKkLGGQDIF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 63044906

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , mass spectrometry (in vitro) ( 3 ) , modification-specific antibody ( 3 ) , mutation of modification site ( 2 , 3 ) , western blotting ( 1 , 2 , 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 , 2 , 3 ) , myocyte-heart ( 2 , 3 ) , neuron ( 1 )

Upstream Regulation
Treatments:
nicotinamide ( 3 ) , nicotinamide riboside ( 2 ) , resveratrol ( 3 ) , siRNA ( 3 ) , trichostatin_A ( 3 )

Downstream Regulation
Effects of modification on SCN5A:
activity, inhibited ( 2 ) , intracellular localization ( 3 )

Disease / Diagnostics Relevance
Relevant diseases:
cardiomyopathy ( 3 )

References 

1

Yoon JY, et al. (2022) Metabolic rescue ameliorates mitochondrial encephalo-cardiomyopathy in murine and human iPSC models of Leigh syndrome. Clin Transl Med 12, e954
35872650   Curated Info

2

Matasic DS, et al. (2020) Modulation of the cardiac sodium channel Na1.5 peak and late currents by NAD precursors. J Mol Cell Cardiol 141, 70-81
32209328   Curated Info

3

Vikram A, et al. (2017) Sirtuin 1 regulates cardiac electrical activity by deacetylating the cardiac sodium channel. Nat Med 23, 361-367
28191886   Curated Info

PhosphoSitePlus® is a registered trademark of Cell Signaling Technology.
Use of PSP data is subject to a formal license agreement. Learn more

©2003-2025 Cell Signaling Technology, Inc.